Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.

Background: The trans-membrane protease serine 2 (TMPRSS2) is essential for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry and infection. Efficacy and safety of TMPRSS2 inhibitors in patients with coronavirus disease 2019 (Covid-19) have not been evaluated in randomized tria...

Full description

Bibliographic Details
Main Authors: Jesper D. Gunst, Nina B. Staerke, Marie H. Pahus, Lena H. Kristensen, Jacob Bodilsen, Nicolai Lohse, Lars S. Dalgaard, Dorthe Brønnum, Ole Fröbert, Bo Hønge, Isik S. Johansen, Ida Monrad, Christian Erikstrup, Regitze Rosendal, Emil Vilstrup, Theis Mariager, Dorthe G. Bove, Rasmus Offersen, Shakil Shakar, Sara Cajander, Nis P. Jørgensen, Sajitha S. Sritharan, Peter Breining, Søren Jespersen, Klaus L. Mortensen, Mads L. Jensen, Lilian Kolte, Giacomo S. Frattari, Carsten S. Larsen, Merete Storgaard, Lars P. Nielsen, Martin Tolstrup, Eva A. Sædder, Lars J. Østergaard, Hien T.T. Ngo, Morten H. Jensen, Jesper F. Højen, Mads Kjolby, Ole S. Søgaard
Format: Article
Language:English
Published: Elsevier 2021-05-01
Series:EClinicalMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537021001292

Internet

http://www.sciencedirect.com/science/article/pii/S2589537021001292

Similar Items